The New Alzheimer’s Drug
This session will discuss Biogen’s new Alzheimer’s drug, Aduhelm – the first FDA-approved drug to slow the progress of this disease in the past 2 decades. We’ll explain the clinical data, and discuss implications for patients and caregivers.
Date July 7, 2021
Hosted By WellMed Charitable Foundation
Dr. Elliot Montgomery Sklar
Dr. Elliot Montgomery Sklar is a public health professional with vast experience in managing health programs and initiatives. With over a decade of practice in supporting the health of the public through academic work, research and service to communities across the Americas, Dr. Sklar shares his passion and expertise in support of diverse caregivers and the complex issues they face.